Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pharmathen s.a. - clopidogrelbesilat - filmovertrukne tabletter - 75 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

maddox pharma swiss b.v. - clopidogrelbesilat - filmovertrukne tabletter - 75 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pharmathen s.a. - clopidogrelbesilat - filmovertrukne tabletter - 75 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

actavis group ptc ehf. - clopidogrelhydrogensulfat - filmovertrukne tabletter - 75 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

medochemie ltd. - clopidogrelhydrogensulfat - filmovertrukne tabletter - 75 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

mylan pharmaceuticals limited - prasugrel besilate - myocardial infarction; acute coronary syndrome; angina, unstable - antitrombotiske midler - prasugrel mylan, co gives sammen med acetylsalicylsyre (asa), er indiceret til forebyggelse af atherothrombotic begivenheder i voksne patienter med akut koronar syndrom (jeg. ustabil angina pectoris, non-st-segment elevation myocardial infarction [ua/nstemi] eller st-segment elevation myocardial infarction [stemi]), der gennemgår primær eller forsinket perkutan koronar intervention (pci).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

the medicines company uk ltd - bivalirudin - akut koronarsyndrom - antitrombotiske midler - angiox er indiceret som antikoagulant til voksne patienter, der gennemgår perkutan koronar intervention (pci), herunder patienter med st-segment-forhøjelse myokardieinfarkt (stemi) under primær pci. angiox er også indiceret til behandling af voksne patienter med ustabil angina / non-st-segment-elevation myocardial infarction (ua / nstemi) planlagte til akutte eller tidlig intervention. angiox bør administreres med acetylsalicylsyre og clopidogrel.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - antitrombotiske midler - xarelto, co-gives sammen med acetylsalicylsyre (asa) alene eller sammen med asa plus clopidogrel eller ticlopidin, der er indiceret til forebyggelse af atherothrombotic hændelser hos voksne patienter efter en akut koronar syndrom (acs) med forhøjet kardiale biomarkører. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. forebyggelse af venøs tromboembolisme (vte) hos voksne patienter, der gennemgår valgfri hofte- eller knæskifteoperation. behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe i voksne. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

merck sharp dohme limited - vorapaxar sulfat - myokardieinfarkt - antitrombotiske midler - zontivityis indiceret til reduktion af atherothrombotic begivenheder i voksne patienter med en historie af myocardial infarction (mi)co-gives sammen med acetylsalicylsyre (asa) og, hvor det er relevant, clopidogrel, eller - symptomatisk, perifer arteriel sygdom(pad), co-gives sammen med acetylsalicylsyre (asa) eller, hvor det er relevant, clopidogrel.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiske midler - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.